Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 13/20 | 0.60 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8417363 | 0.87 | HPGD (0.51) | AOC3MEN1KMT2AADAM17HPGD | |
| SCHEMBL8218633 | 0.83 | PTGES (0.53) | PTGESMEN1KMT2AADAM17 | |
| SCHEMBL6412029 | 0.79 | AOC3 (0.70) | AOC3ABHD6PTGESMEN1KMT2A | |
| SCHEMBL6865230 | 0.75 | HPGD (0.48) | PTGESMEN1KMT2AADAM17HPGD | |
| SCHEMBL17887869 | 0.75 | AOC3 (0.68) | AOC3ABHD6 | |
| SCHEMBL5374253 | 0.72 | HSD17B1 (0.65) | AOC3ABHD6HSD17B1HSD17B2 | |
| SCHEMBL6413145 | 0.72 | AOC3 (0.60) | AOC3ABHD6PTGESMEN1KMT2A | |
| SCHEMBL8414550 | 0.72 | MGLL (0.54) | MEN1KMT2A | |
| SCHEMBL6413143 | 0.72 | AOC3 (0.60) | AOC3ABHD6PTGESMEN1KMT2A | |
| SCHEMBL15263998 | 0.71 | ABHD6 (0.69) | AOC3ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7553864-B2 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20070129378-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | AOC3 1746/4885ABHD6 622/4885PTGES 565/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | AOC3 1731/4885ABHD6 1330/4885PTGES 289/4885 |
| US-20070129378-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, PCSK9, ALPI | AOC3 1798/4885ABHD6 832/4885PTGES 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.